Article

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants

2021-04-01

Abstract excerpt

<h4>Summary</h4> A wide range of SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) were reported to date, most of which target the spike glycoprotein and in particular its receptor binding domain (RBD) and N-terminal domain (NTD) of the S1 subunit. The therapeutic implementation of these antibodies has been recently challenged by emerging SARS-CoV-2 variants that harbor extensively mutated spike versions. Cons...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4e03756e-c3c4-5aad-a950-1e67ad1c04d7
DOI: 10.1101/2021.04.01.438035

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variantsDOI 10.1101/2021.04.01.438035Read

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variantsSemantic proximity Read

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strainsSemantic proximity Read

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domainSemantic proximity Read

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibodySemantic proximity Read

Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants by Two Potent SARS-CoV-2 Neutralizing AntibodiesSemantic proximity Read

Broadly neutralizing antibodies against COVID-19Semantic proximity Read

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike proteinSemantic proximity Read

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.Semantic proximity Read

Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infectionSemantic proximity Read

Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?Semantic proximity Read

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.Semantic proximity Read

Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.Semantic proximity Read